Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.130
+0.060 (2.90%)
At close: Aug 26, 2026, 4:00 PM EDT
2.130
0.00 (0.00%)
After-hours: Aug 26, 2026, 4:01 PM EDT
Palisade Bio Revenue
Palisade Bio had revenue of $500.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
717.99
Revenue / Employee
$35,714
Employees
14
Market Cap
371.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Clinuvel Pharmaceuticals | 64.24M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| Opus Genetics | 9.86M |
| SAB Biotherapeutics | 114.70K |
| Lyell Immunopharma | 27.00K |
PALI News
- 15 days ago - Palisade Bio reports Q2 EPS (22c), consensus (5c) - TheFly
- 16 days ago - Palisade Bio Quarterly report: Q2 2026 - Filings
- 16 days ago - Palisade Bio Earnings release: Q2 2026 - Filings
- 25 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 4 weeks ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly
- 6 weeks ago - Palisade Bio management to meet with Piper Sandler - TheFly
- 6 weeks ago - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 2 months ago - Palisade Bio receives FDA clearance to start ulcerative colitis study - TheFly